KYNB Company Profile and Key Details

Kyntra Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $10.65. This means the shares are trading below this model’s fair value.

Short-term trend indicators are bullishly aligned (SMA20 -10.25%, SMA50 -17.68%, SMA200 -21.94%). The stock’s 14-day RSI is 37.25 (weak momentum), while the ATR of 0.61 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -46.07% below its high and over 43.71% above its low. Average 10-day trading volume of 25.29 thousand shares is slightly above the 3-month average of 22.32 thousand, indicating heightened recent market interest.

The stock is currently mid-range between its 52-week high and low $6.32 and $12.58. With a market capitalization of about $32.26 million, Kyntra Bio, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.06). Key stats such as the average daily volume over the past year has been around 15.34 thousand shares, volume is running light vs its 52-week average. Headquartered in San Francisco, CA, Kyntra Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Thane Wettig, the company employs approximately 34 people and listed since November 14, 2014. Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction.

Kyntra Bio, Inc. generated EPS of $40.44 over the past year. Five-year average earnings growth is 11.75%. Wall Street analysts project EPS growth of -6.88% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $35.00 to $30.00. The high target offers 339.15% upside. The low target suggests 276.41% downside. The mean target is $32.50. This offers 307.78% upside. Kyntra Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by 47.17%. The prior quarter beat by 11.9%. Over the last six quarters, Apple has recorded several small beats. These include -633.33% in May 12, 2025.

Kyntra Bio, Inc. trades at a P/E ratio of 0.14, slightly below the S&P 500 average, with a price-to-sales ratio of 6.94 and a price-to-book ratio of -1.06 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.84, also above market averages.

Kyntra Bio, Inc. (NASDAQ:KYNB) shares are flat -2.62% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Kyntra Bio, Inc. trading at a premium to the broader market with a P/E of 0.14. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $32.50, suggesting 307.78% upside. Our AI forecast model points to short-term strength (9.66% over two weeks), a medium-term fall (-77.29% over three months), and a longer-term gain (62.74% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Kyntra Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.66%, with price expected at $8.74 by September 25, 2026, within a range of $8.47 to $9.04 3-Month Outlook: Projected fall of -77.29%, reaching $1.81 by December 09, 2026, with a range of $1.72 to $1.91. 1-Year Outlook: Projected gain of 62.74%, with price at $12.97 by September 10, 2027, within a range of $12.90 to $13.03.